| Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. | |
| | |
MedLine Citation:
|
PMID: 21055895 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Rosiglitazone is a potent synthetic peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist which improves glucose control in the plasma and reduces ischemic brain injury. However, the pharmacokinetics of rosiglitazone in the brain is still unclear. In this study, a method using liquid chromatography-mass spectrometry coupled with microdialysis and an auto-blood sampling system was developed to determine rosiglitazone and glucose concentration in the brain and blood of gerbils subjected to treatment with rosiglitazone (3.0 mg kg(-1), i.p.). The results showed the limit of detection was 0.04 μg L(-1) and the correlation coefficient was 0.9997 for the determination of rosiglitazone in the brain. The mean parameters, maximum drug concentration (C(max)) and the area under the concentration-time curve from time zero to time infinity (AUC(inf)), following rosiglitazone administration were 1.06±0.28 μg L(-1) and 296.82±44.67 μg min L(-1), respectively. The time to peak concentration (C(max) or T(max)) of rosiglitazone occurred at 105±17.10 min, and the mean elimination half-life (t(1/2)) from brain was 190.81±85.18 min after administration of rosiglitazone. The brain glucose levels decreased to 71% of the basal levels in the rosiglitazone-treated group when compared with those in the control (p<0.01). Treatment with rosiglitazone decreased blood glucose levels to 80% at 1h after pretreatment of rosiglitazone (p<0.05). In addition, pretreatment with rosiglitazone significantly reduced the cerebral infarct volume compared with that of the control group. These findings suggest that this method may be useful for simultaneous and continuous determination of rosiglitazone and glucose concentrations in brain and plasma. Rosiglitazone was effective at penetrating the blood-brain barrier as evidenced by the rapid appearance of rosiglitazone in the brain, and rosiglitazone may contribute to a reduction in the extent of injuries related to cerebral ischemic stroke via its hypoglycemic effect. |
| | |
Authors:
|
Wayne H-H Sheu; Hsiu-Chun Chuang; Shiu-Min Cheng; Maw-Rong Lee; Chi-Chi Chou; Fu-Chou Cheng |
Related Documents
:
|
8162935 - Quantitative comparison between 99mtc-hmpao and 99mtc-ecd: measurement of arterial inpu... 2118715 - Role of leukotrienes as mediator compounds in brain edema. 7922575 - Differential effects of competitive (cgs19755) and non-competitive (mk 801) nmda recept... 19781725 - Influence of trypanosoma evansi in blood, plasma, and brain cholinesterase of experimen... 3704505 - Colchicine treatment effects on liver cirrhosis assessed by liver blood flow measurements. 11089105 - Two-dimensional granular flow in a vibrated small-angle funnel |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-16 |
Journal Detail:
|
Title: Journal of pharmaceutical and biomedical analysis Volume: 54 ISSN: 1873-264X ISO Abbreviation: J Pharm Biomed Anal Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2010-12-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309336 Medline TA: J Pharm Biomed Anal Country: England |
Other Details:
|
Languages: eng Pagination: 759-64 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier B.V. All rights reserved. |
Affiliation:
|
Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Extended staging of oesophageal cancer using FDG-PET - A critical appraisal.
Next Document: Components of the porcine anterior pituitary insulin-like growth factor system throughout the estrou...